Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue 2025 revenue was $761 million compared to $675 million in the prior year, representing a year-over-year increase. The growth was attributed to a surge in demand for Cushing's Syndrome medications, with a record number of new prescriptions and first-time prescribers.
Net Income Net income was $99.7 million for the full year 2025 compared to $141.2 million in the prior year, showing a decline. The decrease was not explicitly explained in the transcript.
Cash and Investments Cash and investments at December 31, 2025, were $532 million. This reflects the acquisition of $245 million worth of common stock under the stock repurchase program and shares acquired through stock option exercises and restricted stock vesting.
Cushing's Syndrome Medications (Tablets Sold) There was a 37% increase in tablets sold in 2025 compared to 2024. However, the growth was constrained by a lack of capacity at the previous pharmacy vendor, which was addressed by transitioning to a new specialty pharmacy in October.
New Prescriptions for Cushing's Syndrome Medications There was a 61% increase in the number of new prescriptions in 2025 compared to 2024. The gap between new prescriptions and tablets sold was due to the pharmacy vendor's capacity issues.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Relacorilant: FDA did not approve relacorilant for Cushing's syndrome despite meeting primary endpoint in GRACE trial. The company plans to appeal or resubmit the NDA.
Korlym: Record number of new prescriptions and first-time prescribers in 2025. Transition to a new specialty pharmacy to meet demand.
Relacorilant in Oncology: Positive results in Phase III ROSELLA trial for platinum-resistant ovarian cancer. FDA PDUFA date set for July 11, 2026.
Dazucorilant: Encouraging results in ALS trial with 84% reduction in risk of death. Plans for a pivotal trial later this year.
Cushing's Syndrome Market: Surge in demand for Korlym in 2025. Catalyst trial findings expected to drive growth to $2 billion annual revenue by the end of the decade.
Oncology Market: Relacorilant expected to become standard of care for platinum-resistant ovarian cancer. Expansion into other solid tumors and combination therapies.
Pharmacy Transition: Transitioned to a new specialty pharmacy to address capacity issues, disrupting business temporarily but expected to improve performance.
Stock Repurchase Program: Acquired $245 million worth of common stock in 2025.
FDA Engagement: Plans to meet with FDA to address relacorilant's rejection and explore resubmission or appeal.
Pipeline Expansion: Advancing trials in oncology, metabolic, and neurological indications, including ALS and MASH.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Legal Risks: The Federal Circuit Court of Appeals ruled against Corcept Therapeutics in their lawsuit to stop Teva Pharmaceuticals from marketing a generic version of Korlym, which could lead to significant revenue loss. Corcept plans to appeal the decision.
Regulatory Challenges: The FDA's failure to approve relacorilant as a treatment for Cushing's syndrome was unexpected, despite meeting the primary endpoint in the GRACE trial. This could delay the availability of the drug and impact revenue growth.
Operational Disruptions: Transitioning to a new specialty pharmacy caused disruptions in November, December, and January, leading to a gap between new prescriptions and tablets sold. This affected the company's ability to meet demand.
Market Competition: The potential entry of Teva's generic version of Korlym could increase competitive pressures and reduce market share for Corcept's Cushing's syndrome treatments.
Supply Chain Limitations: The previous pharmacy vendor's lack of capacity to meet increasing demand for medications created operational inefficiencies, though this issue is being addressed with a new vendor.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects its revenue to grow to $900 million to $1 billion for the full year 2026, up from $761 million in 2025.
Cushing's Syndrome Business: The company anticipates its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade. Growth is expected to accelerate further with the approval of relacorilant.
Relacorilant Approval for Cushing's Syndrome: The company plans to meet with the FDA in April to discuss the approval of relacorilant for Cushing's syndrome. Potential outcomes include resubmission of the NDA, filing a formal appeal, or conducting a new study.
Relacorilant Approval for Oncology: The company expects relacorilant to receive FDA approval for platinum-resistant ovarian cancer by mid-2026, with a PDUFA date set for July 11, 2026.
Oncology Trials: The company plans to release results from its BELLA study in platinum-resistant ovarian cancer by the end of 2026 and from other oncology trials by the end of 2027.
MONARCH Trial for MASH: The company expects results from its Phase IIb MONARCH trial in MASH by the end of 2026. If positive, the company will advance to Phase III.
ALS Drug Development: The company plans to begin a Phase III study for dazucorilant in ALS patients by mid-2026, following up on positive Phase II results.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: Cash and investments at December 31, 2025, were $532 million, which reflects our acquisition in 2025 of $245 million worth of our common stock pursuant to our stock repurchase program as well as shares acquired upon the exercise of Corcept stock options and the vesting of restricted stock rates.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's thoughts on the CRL and the FDA's decision?
A:The company believes their data met the scientific basis for approval and aligned with prior approved treatments. They are unsure of the FDA's reasoning and plan to meet with the agency in April to understand their decision.
Q:What are the assumptions in the guidance for Korlym, particularly regarding net price erosion and AG prescriptions?
A:The AG's net price is about a 30% discount on Korlym's WAC. By the end of 2025, 75% of the volume shifted to AG prescriptions, and this increased to 78% in 2026. The company expects stabilization with potential pricing pressures and discounting through 2026.
Q:What is the likelihood of running a randomized relacorilant trial for type 2 diabetes or hypertensive patients?
A:The company emphasized the importance of identifying and treating hypercortisolism in patients with resistant diabetes and hypertension. They did not confirm plans for a randomized trial but highlighted the significance of their findings in hypercortisolism.
Q:What should be expected from the ROSELLA data presentation at SGO in April?
A:The presentation will include the full Kaplan-Meier curve, full safety data sets, and findings showing the tolerability of relacorilant in combination with nab-paclitaxel. The company expects early and broad adoption of the regimen as a potential new standard of care.
Q:How confident is the company in resolving supply chain issues and specialty pharmacy challenges?
A:The company transitioned all patients to Curant, a pharmacy with over 25 years of expertise in the orphan space. They are seeing improvements in metrics and are confident in Curant's ability to scale with their business.
Q:How much of the guidance includes relacorilant revenues from the oncology franchise?
A:Almost all of the guidance range comes from the Cushing's Syndrome business, with only a small portion from the oncology business due to the anticipated timing of the oncology launch.
Q:What is the safety profile of relacorilant in the ROSELLA trial and its comparison to the endocrinology program?
A:The safety profile in the ROSELLA trial is consistent with previous findings, showing no significant ALT rises. In fact, ALT rises were lower in the combination arm compared to nab-paclitaxel alone. The endocrinology program also showed no cases of drug-induced liver injury.
Q:How does the company view the impact of KEYTRUDA on their oncology regimen?
A:KEYTRUDA's approval is limited to patients with CPS greater than 1, representing 50%-60% of the population. The company believes their regimen offers broader applicability and maintains options for oncologists, with KEYTRUDA being used in later lines of therapy.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the likelihood of running a randomized relacorilant trial for type 2 diabetes or hypertensive patients, instead emphasizing the importance of identifying and treating hypercortisolism. They also did not provide specific details on how they plan to bridge the gap between their position and the FDA's decision on the CRL.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Corcept
GRACE patient
GRACE trial
NDA FDA
NDA development
Relacorilant
amount NDA
benefit
blood pressure
capacity pharmacy
cause optimism
condition
decrease
deficiency
demand
design trial
development program
evidence
example
file
filing
instruction
label
meeting
need
number patient
number prescription
patient Cushing
patient diabetes
patient medication
phase patient
reason approval
recommendation
record number
response letter
review
sponsor
syndrome hypertension
syndrome medication
CORT Transcript
Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture: revenue growth and strategic expansion in pharmacy capacity are positive, but the significant drop in net income and lack of priority review for the ovarian cancer NDA are concerns. The Q&A reveals confidence in handling increased volume and no downward pressure on margins, but management's vague responses on certain issues may worry investors. The market cap is moderate, suggesting a neutral stock price movement, balancing positive growth prospects with current financial challenges.
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call summary and Q&A reveal strong revenue growth, a strategic sales force expansion, and a promising drug pipeline. Despite minor setbacks in pharmacy capacity impacting financial results, the company's stock repurchase program and optimistic future revenue expectations, particularly for relacorilant, are positive indicators. The Q&A also highlighted management's proactive measures to address pharmacy issues and expand market reach. With a market cap of $3.3 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Unknown5-5
The earnings call presents mixed signals: strong revenue growth and promising drug developments are offset by regulatory risks, competitive pressures, and a decline in net income. The stock repurchase program is a positive factor, but the transition to lower-priced generics and unresolved patent litigation pose significant risks. The market cap suggests moderate sensitivity to these factors. Overall, the sentiment is neutral, as the positive developments are balanced by the risks and challenges faced by the company.
CORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
